May 28, 2020
Mylan Institutional is recalling more than 3000 vials of Aloprim (allopurinol sodium) injection because of product discoloration, according to the May 27, 2020, US Food and Drug Administration (FDA) Enforcement Report.
The recall affects 500-mg single-dose vials of Aloprim (NDC 67457-187-50) from lots N1700771 (Exp. 10/20) and N1800127 (Exp. 2/21). The vials were distributed throughout the United States.
Mylan Institutional initiated the voluntary recall May 5, 2020. The FDA designated the recall Class II on May 20, 2020. Drugs affected by Class II recalls may cause temporary or medically reversible adverse health consequences if used. While remote, a possibility of serious harm also exists.
Aloprim is a prescription medication that reduces uric acid. It is used to treat gout and kidney stones.